CD79A and selective IgA deficiency disease: As a consequence of the diagnostic efficacy of the antibodies and their compatibility with the biopsy results, The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) does not recommend the routine use of biopsy for CD in children in 2022.16,17 ESPGHAN guidelines in 2012 recommend TG-IgA testing, which is highly sensitive and specific, and less costly than EMA IgA antibody test as an initial screening test for suspected CD, and total IgA to rule out selective IgA deficiency.